JP2009542702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542702A5 JP2009542702A5 JP2009518404A JP2009518404A JP2009542702A5 JP 2009542702 A5 JP2009542702 A5 JP 2009542702A5 JP 2009518404 A JP2009518404 A JP 2009518404A JP 2009518404 A JP2009518404 A JP 2009518404A JP 2009542702 A5 JP2009542702 A5 JP 2009542702A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- human
- item
- individual
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 21
- 230000002503 metabolic effect Effects 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 235000012631 food intake Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000036186 satiety Effects 0.000 claims description 4
- 235000019627 satiety Nutrition 0.000 claims description 4
- 230000004584 weight gain Effects 0.000 claims description 4
- 235000019786 weight gain Nutrition 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 29
- 230000004060 metabolic process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81950006P | 2006-07-06 | 2006-07-06 | |
| PCT/US2007/015681 WO2008005576A1 (en) | 2006-07-06 | 2007-07-05 | Modulators of metabolism and the treatment of disorders related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009542702A JP2009542702A (ja) | 2009-12-03 |
| JP2009542702A5 true JP2009542702A5 (enExample) | 2011-08-18 |
Family
ID=38707392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518404A Withdrawn JP2009542702A (ja) | 2006-07-06 | 2007-07-05 | 代謝の調節因子および代謝に関連する障害の処置 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20100004272A1 (enExample) |
| EP (1) | EP2049523A1 (enExample) |
| JP (1) | JP2009542702A (enExample) |
| KR (1) | KR20090024779A (enExample) |
| CN (1) | CN101484440A (enExample) |
| AR (1) | AR061967A1 (enExample) |
| AU (1) | AU2007269577A1 (enExample) |
| BR (1) | BRPI0714006A2 (enExample) |
| CA (1) | CA2656520A1 (enExample) |
| CL (1) | CL2007001972A1 (enExample) |
| CO (1) | CO6160320A2 (enExample) |
| CR (1) | CR10538A (enExample) |
| EA (1) | EA015343B1 (enExample) |
| EC (1) | ECSP099036A (enExample) |
| GT (1) | GT200800305A (enExample) |
| IL (1) | IL195819A0 (enExample) |
| MA (1) | MA30601B1 (enExample) |
| MX (1) | MX2008016251A (enExample) |
| NI (1) | NI200800328A (enExample) |
| NO (1) | NO20090590L (enExample) |
| PE (1) | PE20080737A1 (enExample) |
| TN (1) | TNSN08534A1 (enExample) |
| TW (1) | TW200811140A (enExample) |
| UY (1) | UY30466A1 (enExample) |
| WO (1) | WO2008005576A1 (enExample) |
| ZA (1) | ZA200900051B (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| HRP20050696B1 (en) | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| BRPI0817211A2 (pt) | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| WO2010059384A1 (en) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| WO2010095663A1 (ja) | 2009-02-18 | 2010-08-26 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| BR112012000831A2 (pt) | 2009-06-24 | 2019-09-24 | Boehringer Ingelheim Int | compostos, composições farmacêuticas e métodos relacionados |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| US8886788B2 (en) * | 2009-08-31 | 2014-11-11 | Accenture Global Services Limited | Enterprise-level management, control and information aspects of cloud console |
| PH12012501037A1 (en) | 2009-11-27 | 2013-01-14 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
| MX2013003184A (es) | 2010-09-22 | 2013-06-07 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo. |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| EP2643311A1 (en) | 2010-11-26 | 2013-10-02 | Lupin Limited | Bicyclic gpr119 modulators |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| US9755858B2 (en) * | 2014-04-15 | 2017-09-05 | Cisco Technology, Inc. | Programmable infrastructure gateway for enabling hybrid cloud services in a network environment |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN104725308A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN106749179A (zh) * | 2015-03-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和哌啶结构ptp1b抑制剂及其用途 |
| CN106831559A (zh) * | 2015-03-12 | 2017-06-13 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104761540A (zh) * | 2015-03-12 | 2015-07-08 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和哌啶结构的化合物及其用途 |
| CN106748998A (zh) * | 2015-03-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺结构的ptp1b抑制剂及其用途 |
| CN104788425A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途 |
| CN104725306A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104788424A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途 |
| CN104725311A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺结构的ptp1b抑制剂及其用途 |
| CN104725312A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和苯胺结构的ptp1b抑制剂、其制备及用途 |
| CN106831560A (zh) * | 2015-03-12 | 2017-06-13 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和苯胺结构的ptp1b抑制剂及其用途 |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CN107145725A (zh) * | 2017-04-26 | 2017-09-08 | 江南大学 | 一种分析餐厨垃圾厌氧消化产甲烷能力的方法 |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH478817A (de) * | 1965-10-22 | 1969-09-30 | Ciba Geigy | Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen |
| CH480410A (de) * | 1967-01-09 | 1969-10-31 | Geigy Ag J R | Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen |
| CA961052A (en) * | 1967-01-12 | 1975-01-14 | Max Schellenbaum | N-2-ethylhexyl-n'-aryl ureas and preparation containing them |
| US3608087A (en) * | 1968-06-21 | 1971-09-21 | Merck & Co Inc | Feed compositions |
| US3887329A (en) * | 1969-05-05 | 1975-06-03 | Ciba Geigy Ag | Hexamethyl phosphotriamide-dye compositions |
| US3686238A (en) * | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US3852434A (en) * | 1970-09-11 | 1974-12-03 | Merck & Co Inc | Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof |
| US3966744A (en) * | 1971-01-11 | 1976-06-29 | Syva Company | Spin labeled compounds |
| US3690834A (en) * | 1971-01-11 | 1972-09-12 | Syva Co | Ligand determination with spin labeled compounds by receptor displacement |
| DE2106585A1 (de) * | 1971-02-11 | 1972-08-24 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Aminothiodiazole und Thiodiazol-Azofarbstoffe |
| US3966764A (en) * | 1972-07-10 | 1976-06-29 | Syva Company | Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs |
| US3849420A (en) * | 1972-10-20 | 1974-11-19 | Dow Chemical Co | Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines |
| CH574206A5 (enExample) * | 1972-11-16 | 1976-04-15 | Ciba Geigy Ag | |
| DE2340569C2 (de) * | 1973-08-10 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Azofarbstoffe |
| AT340933B (de) * | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| US4101541A (en) * | 1973-12-21 | 1978-07-18 | Ciba-Geigy Corporation | 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs |
| FR2306697A1 (fr) * | 1975-04-10 | 1976-11-05 | Sogeras | Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants |
| DE2731264A1 (de) * | 1977-07-11 | 1979-02-01 | Boehringer Mannheim Gmbh | Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen |
| JPS6038696B2 (ja) * | 1977-12-09 | 1985-09-02 | コニカ株式会社 | ハロゲン化銀カラ−写真感光材料 |
| US4242507A (en) * | 1978-02-23 | 1980-12-30 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonic acid esters |
| DE2831580C2 (de) * | 1978-07-18 | 1980-09-18 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und Reagens zur Bestimmung von Glycerin |
| DE2906603A1 (de) * | 1979-02-21 | 1980-09-04 | Boehringer Mannheim Gmbh | N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel |
| DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| DE3334455A1 (de) * | 1983-03-04 | 1984-09-06 | Bayer Ag, 5090 Leverkusen | Guanidin - derivate |
| ZA848275B (en) * | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
| DE3601196A1 (de) * | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-dihydropyridine |
| US5364865A (en) * | 1992-12-30 | 1994-11-15 | Sterling Winthrop Inc. | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| PT781766E (pt) * | 1994-09-09 | 2004-07-30 | Nippon Shinyaku Co Ltd | Derivado heterociclico e medicamento |
| US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US6956047B1 (en) * | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US5849759A (en) * | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| US5948786A (en) * | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US6008234A (en) * | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6239126B1 (en) * | 1998-12-17 | 2001-05-29 | American Home Products Corporation | Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives |
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US6525064B1 (en) * | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| HRP20050696B1 (en) * | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| ES2316964T3 (es) * | 2003-02-24 | 2009-04-16 | Arena Pharmaceuticals, Inc. | Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa. |
| US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| US7132426B2 (en) * | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| UA92150C2 (ru) * | 2004-06-04 | 2010-10-11 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
-
2007
- 2007-07-02 TW TW096124027A patent/TW200811140A/zh unknown
- 2007-07-04 PE PE2007000858A patent/PE20080737A1/es not_active Application Discontinuation
- 2007-07-05 AU AU2007269577A patent/AU2007269577A1/en not_active Withdrawn
- 2007-07-05 CA CA002656520A patent/CA2656520A1/en not_active Abandoned
- 2007-07-05 EP EP07810288A patent/EP2049523A1/en not_active Withdrawn
- 2007-07-05 EA EA200970090A patent/EA015343B1/ru not_active IP Right Cessation
- 2007-07-05 US US12/307,545 patent/US20100004272A1/en not_active Abandoned
- 2007-07-05 WO PCT/US2007/015681 patent/WO2008005576A1/en not_active Ceased
- 2007-07-05 CL CL200701972A patent/CL2007001972A1/es unknown
- 2007-07-05 JP JP2009518404A patent/JP2009542702A/ja not_active Withdrawn
- 2007-07-05 MX MX2008016251A patent/MX2008016251A/es not_active Application Discontinuation
- 2007-07-05 CN CNA2007800249135A patent/CN101484440A/zh not_active Withdrawn
- 2007-07-05 BR BRPI0714006-1A patent/BRPI0714006A2/pt not_active IP Right Cessation
- 2007-07-05 KR KR1020097000109A patent/KR20090024779A/ko not_active Withdrawn
- 2007-07-06 AR ARP070103026A patent/AR061967A1/es unknown
- 2007-07-06 UY UY30466A patent/UY30466A1/es unknown
-
2008
- 2008-12-09 IL IL195819A patent/IL195819A0/en unknown
- 2008-12-15 NI NI200800328A patent/NI200800328A/es unknown
- 2008-12-19 CR CR10538A patent/CR10538A/es not_active Application Discontinuation
- 2008-12-24 CO CO08136751A patent/CO6160320A2/es unknown
- 2008-12-25 TN TNP2008000534A patent/TNSN08534A1/en unknown
- 2008-12-29 GT GT200800305A patent/GT200800305A/es unknown
-
2009
- 2009-01-05 ZA ZA200900051A patent/ZA200900051B/xx unknown
- 2009-01-06 EC EC2009009036A patent/ECSP099036A/es unknown
- 2009-01-27 MA MA31590A patent/MA30601B1/fr unknown
- 2009-02-06 NO NO20090590A patent/NO20090590L/no not_active Application Discontinuation